Circulogene Accepts First International Orders for Cell-Free DNA Liquid Biopsy Testing

Single-blood-drop, high-yield DNA testing drives international demand
for Circulogene’s fast, accurate, cancer monitoring and treatment
products

BIRMINGHAM, Ala.–(BUSINESS WIRE)–Circulogene
Theranostics
, the only biotechnology company able to enrich
circulating cell-free DNA (cfDNA) from a single blood drop for
patient-specific monitoring of cancer, has received the first
international orders for its liquid biopsy testing products from Turkey,
Hungary and Israel. The news comes less than three months after the
company formally launched
its cfDNA tumor detection and monitoring products, which enable fast,
accurate and personalized testing of 10 tumor types, including breast,
lung and colon cancer.

“Our single-blood-drop value proposition has gained significant
international attention,” said Circulogene Chief Commercial Officer
James Straza. “In addition to growing demand here in the U.S., other
countries and governmental organizations see tremendous value in
blood-drop-volume samples that deliver maximum output from minimum
input.”

Non-invasive liquid biopsies represent a major advance over traditional
surgical tumor biopsies, which are costly, time consuming and only
sample a small portion of tumor tissue, leading to a high failure rate.
However, even current industry-standard liquid biopsy methods require
large sample amounts, and DNA loss from the extraction process can miss
critical tumor information, which can significantly change a patient’s
treatment and prognosis.

“We’re particularly interested in Circulogene’s proprietary DNA
enrichment capabilities, because it results in near-full recovery of
cfDNA from finger-stick volumes of blood,” said Ati Goknur, COO of GGT
Global Genetik, which is distributing in Turkey. “The small-volume blood
samples are easily shipped, and we’re able to gain a wealth of DNA
information, giving our medical experts in Istanbul, as well as the rest
of Turkey, the most accurate testing and personalized cancer management
capabilities available in the market today.”

The company’s proprietary
method
can collect more than 100 times more cfDNA with just 1/10 of
the blood (as little as 20 microliters) compared to the current industry
standard for non-invasive liquid biopsy testing. Circulogene’s liquid
biopsy testing is capable of detecting nearly 3000 cancer mutations on
50 well-established cancer-associated genes for its 10 cancer profiles.

Once cancer has been diagnosed in a patient, Circulogene’s laboratory
can report testing results back to physicians in a matter of days to aid
them in selecting the right therapy at the right time for each patient’s
unique situation.

Circulogene is Clinical Laboratory Improvement Amendments (CLIA)
certified, and it plans to expand research initiatives to independently
demonstrate greatly increased sensitivity and specificity compared to
current methods. For more information, visit our website,
connect with us on LinkedIn,
email us at info@circulogene.com
or call 205-278-1600. Clinicians interested in ordering the test may
visit the Contact
page on Circulogene’s website.

About Circulogene Theranostics

Headquartered in Birmingham, Ala., Circulogene Theranostics is an
innovative molecular diagnostics company founded and operated by a team
of experienced industry executives and skilled molecular diagnostics
scientists. Applying its proprietary laboratory developed test for cfDNA
liquid biopsies, Circulogene has developed the first droplet-volume,
next-generation sequencing (NGS) method to provide full genomic load
analysis, enabling more accurate data to help clinicians and their
patients. For more information, visit
www.circulogene.com
or call 205-278-1600.

Contacts

Circulogene Theranostics
Media Contact
Armada
Medical Marketing
Dan Snyders, 303-623-1190 ext. 230
dan@armadamedical.com
or
Company
Contact

Scott Rezek, 205-278-1607
srezek@Circulogene.com